"Aprotinin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
| Descriptor ID |
D007611
|
| MeSH Number(s) |
D12.776.083
|
| Concept/Terms |
Aprotinin- Aprotinin
- Trypsin Inhibitor, Basic, Pancreatic
- Bovine Kunitz Pancreatic Trypsin Inhibitor
- BPTI, Basic Pancreatic Trypsin Inhibitor
- Kallikrein-Trypsin Inactivator
- Inactivator, Kallikrein-Trypsin
- Kallikrein Trypsin Inactivator
- Kunitz Pancreatic Trypsin Inhibitor
- Trypsin Inhibitor, Kunitz, Pancreatic
- Basic Pancreatic Trypsin Inhibitor
- Bovine Pancreatic Trypsin Inhibitor
Contrykal- Contrykal
- Kontrykal
- Kontrikal
- Contrical
|
Below are MeSH descriptors whose meaning is more general than "Aprotinin".
Below are MeSH descriptors whose meaning is more specific than "Aprotinin".
This graph shows the total number of publications written about "Aprotinin" by people in this website by year, and whether "Aprotinin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Aprotinin" by people in Profiles.
-
Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients. Viruses. 2021 06 27; 13(7).
-
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020 Dec 09; 21(1):1005.
-
Aprotinin Inhibits SARS-CoV-2 Replication. Cells. 2020 10 30; 9(11).
-
Methylene blue may have a role in the treatment of COVID-19. Med Hypotheses. 2020 Nov; 144:110163.
-
Personality traits and facets linked with self-reported alcohol consumption and biomarkers of liver health. Addict Behav. 2018 07; 82:135-141.
-
Aprotinin as an alternative to tranexamic acid in cardiac surgery - Is this where we started from? Anaesth Crit Care Pain Med. 2017 04; 36(2):79-81.
-
A special article following the relicence of aprotinin injection in Europe. Anaesth Crit Care Pain Med. 2017 04; 36(2):97-102.
-
[Use of Tachocomb agent in cardiovascular surgery]. Angiol Sosud Khir. 2017; 23(3):173-176.
-
Con: Aprotinin should not be used in cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2007 Apr; 21(2):302-4.
-
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 2004 May; 18(7):828-35.